SPBC106.03 Antibody

What is SPBC106.03 and why develop antibodies against it?

SPBC106.03 (UniProtKB: Q9URV8) is an uncharacterized protein in Schizosaccharomyces pombe (fission yeast), classified as a UPF0744 family protein. Developing antibodies against this protein is valuable for several reasons:

• It enables functional characterization of previously uncharacterized genes in the S. pombe genome

• It allows researchers to determine subcellular localization and expression patterns

• It facilitates the identification of protein interaction partners

• It supports comparative genomics studies between different yeast species

Antibodies against uncharacterized proteins like SPBC106.03 are essential tools for bridging genomic annotation with functional characterization, particularly in model organisms like S. pombe that share conserved regulatory processes with humans .

What is the current state of knowledge about SPBC106.03?

SPBC106.03 remains largely uncharacterized based on current literature. Key points include:

• It is annotated in UniProt (Q9URV8) with limited functional information

• It belongs to the UPF0744 protein family in S. pombe strain 972 / ATCC 24843

• It is not among the well-studied transcription factors or regulatory proteins in recent comprehensive S. pombe studies

• There are no experimentally validated interaction partners reported in BioGRID or other interaction databases

This lack of characterization makes SPBC106.03 an interesting target for antibody-based studies to determine its function within the fission yeast cellular system.

What approaches are used to generate antibodies against S. pombe proteins like SPBC106.03?

Several approaches can be used to generate antibodies against S. pombe proteins:

The recombinant protein approach typically involves cloning SPBC106.03 into expression vectors like pGEX-4T-1 for GST fusion proteins or pET vectors for His-tagged proteins, followed by expression in E. coli, purification, and immunization . This is similar to the approach used for commercial antibodies against other S. pombe proteins .

How should experiments be designed to validate SPBC106.03 antibody specificity?

A comprehensive validation strategy should include:

• Genetic validation:

  • Compare Western blot results between wild-type and SPBC106.03 deletion strains

  • The deletion strain can be generated using the one-step gene replacement method with appropriate selection markers (kanMX6, hphMX6)

• Biochemical validation:

  • Peptide competition assay (pre-incubating antibody with immunizing peptide/protein)

  • Immunoblotting with recombinant SPBC106.03 protein as positive control

  • Testing pre-immune serum as negative control

• Orthogonal validation:

  • Create an epitope-tagged version of SPBC106.03 (e.g., 13Myc-SPBC106.03) and compare detection with both anti-SPBC106.03 and anti-tag antibodies

  • Mass spectrometry confirmation of immunoprecipitated proteins

• Cross-reactivity assessment:

  • Testing against closely related S. pombe proteins

  • Examining reactivity in other yeast species

Each validation experiment should include appropriate controls and be performed in biological triplicates to ensure statistical significance of the results.

What is the optimal immunoprecipitation protocol for SPBC106.03 using specific antibodies?

Based on successful immunoprecipitation protocols for S. pombe proteins, an optimized protocol would include:

• Cell preparation:

  • Grow 50-100ml S. pombe culture to OD600 0.5-0.8

  • Harvest cells by centrifugation (3,000×g, 5 min, 4°C)

  • Wash with ice-cold PBS

• Cell lysis:

  • Resuspend in lysis buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100, protease inhibitor cocktail)

  • Lyse using glass beads (5-7 cycles of 1 min vortexing, 1 min ice)

  • Clear lysate by centrifugation (16,000×g, 10 min, 4°C)

• Immunoprecipitation:

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C)

  • Incubate with anti-SPBC106.03 antibody (2-5μg) overnight at 4°C

  • Add Protein A/G beads and incubate 2-3 hours at 4°C

  • Wash 4× with lysis buffer (testing both 150mM and 500mM NaCl conditions)

  • Elute with SDS sample buffer or perform on-bead digestion for mass spectrometry

• Controls:

  • IgG control IP

  • Input sample (5-10% of lysate)

  • IP from SPBC106.03 deletion strain

This protocol has been effective for similar S. pombe proteins and incorporates both low and high stringency conditions to distinguish stable from transient interactions .

How can ChIP-seq experiments be designed to study SPBC106.03 DNA binding if it has chromatin-associated functions?

If SPBC106.03 is suspected to interact with chromatin, a ChIP-seq protocol should be designed following successful approaches used for other S. pombe proteins:

• Cross-linking and chromatin preparation:

  • Crosslink cells with 1% formaldehyde for 15 minutes at room temperature

  • Quench with 125mM glycine for 5 minutes

  • Lyse cells and sonicate to generate 200-500bp chromatin fragments

  • Verify fragmentation by agarose gel electrophoresis

• Immunoprecipitation:

  • Pre-clear chromatin with Protein A/G beads

  • Incubate with anti-SPBC106.03 antibody overnight at 4°C

  • Include appropriate controls (IgG, input DNA)

  • Perform stringent washes (varying salt concentrations)

  • Reverse crosslinks (65°C overnight)

  • Purify DNA using column-based methods

• Sequencing and analysis:

  • Prepare libraries following standard protocols

  • Sequence to minimum depth of 10-20 million reads

  • Align to S. pombe genome (assembly ASM294v2)

  • Call peaks using MACS2 with ≥2-fold enrichment threshold

  • Filter out blacklisted regions and artifacts

• Validation and interpretation:

  • Calculate correlation between replicates

  • Perform motif discovery analysis

  • Compare binding sites with gene expression data

  • Integrate with histone modification and nucleosome occupancy data

ChIP experiments should be performed in biological duplicates to ensure reproducibility, following approaches that have successfully identified binding sites for other S. pombe proteins .

How do you analyze mass spectrometry data from SPBC106.03 immunoprecipitation experiments?

Robust analysis of IP-MS data for SPBC106.03 should follow these steps:

• Data preprocessing:

  • Raw data conversion and peak picking

  • Peptide and protein identification using search engines (e.g., MaxQuant, Mascot)

  • Database search against S. pombe proteome with appropriate parameters

  • Filter identifications (1% FDR at peptide and protein levels)

• Quantitative analysis:

  • Normalize data (total spectral counts or intensity-based)

  • Compare SPBC106.03-IP with control IPs (IgG or unrelated protein)

  • Apply statistical testing:

    • Calculate moderated t-statistics to identify significant interactors

    • Implement fold-change thresholds (log2FC > 1)

    • Apply multiple testing correction (Benjamini-Hochberg)

  • Use different stringency thresholds:

    • Stringent: adjusted p-value < 2e-4 & log2FC > 1

    • Moderate: adjusted p-value < 0.01 & log2FC > 1

• Interactome filtering:

  • Remove common contaminants (using CRAPome database)

  • Compare interactions identified at different salt concentrations (150mM vs. 500mM NaCl)

  • Identify core stable interactors versus condition-specific interactions

• Functional interpretation:

  • Classify interactors by GO terms and protein families

  • Identify potential complexes through clustering analysis

  • Compare with known interaction networks in S. pombe

  • Integrate with genetic interaction data when available

What strategies can address poor signal-to-noise ratio when using SPBC106.03 antibodies?

When encountering high background or weak specific signals with SPBC106.03 antibodies, implement these optimization strategies:

• For Western blotting:

  • Blocking optimization: Test different blocking agents (5% BSA, 5% milk, commercial blockers) and longer blocking times (overnight at 4°C)

  • Antibody titration: Perform dilution series (1:500 to 1:5000) to identify optimal concentration

  • Buffer modifications: Increase Tween-20 concentration (0.1% to 0.3%) in wash buffers

  • Incubation conditions: Test both room temperature (1-2 hours) and 4°C (overnight) incubations

  • Detection systems: Compare HRP vs. fluorescent secondary antibodies

• For immunoprecipitation:

  • Pre-clearing optimization: Extend pre-clearing time or use multiple pre-clearing steps

  • Buffer stringency: Systematically test increasing salt concentrations (150mM to 500mM NaCl)

  • Detergent modifications: Add secondary detergents (0.1% SDS, 0.5% sodium deoxycholate)

  • Bead optimization: Compare different types of beads (agarose, magnetic, sepharose)

  • Antibody coupling: Crosslink antibody to beads to reduce heavy/light chain interference

• For immunofluorescence:

  • Fixation optimization: Compare different fixatives (formaldehyde, methanol) and times

  • Permeabilization: Test different permeabilization agents (Triton X-100, digitonin, saponin)

  • Signal amplification: Implement tyramide signal amplification or higher sensitivity detection systems

  • Autofluorescence reduction: Add quenching steps (sodium borohydride, ammonium chloride)

Each optimization should be performed systematically with appropriate controls to identify conditions that maximize specific signal while minimizing background.

How can epitope tagging complement or replace antibody-based detection of SPBC106.03?

Epitope tagging provides powerful alternatives when specific antibodies show limitations:

• Tagging strategies for S. pombe genes:

  • C-terminal tagging: 3xFLAG, 13Myc, 3HA, GFP using homologous recombination

  • Selection markers: kanMX6, hphMX6, ura4+, leu1+

  • Design of homology arms: 80-100bp flanking sequences

  • PCR verification and sequencing to confirm correct integration

• Advantages over direct antibodies:

  • Utilizes well-characterized commercial tag antibodies with validated performance

  • Enables comparison across different proteins using identical detection methods

  • Circumvents issues of antibody batch variation and specificity

  • Facilitates tandem affinity purification for complex isolation

  • Enables live-cell imaging when using fluorescent protein tags

• Potential limitations:

  • Tag might interfere with protein function or localization

  • Expression from native locus might yield low signals for low-abundance proteins

  • Requires genetic manipulation of the organism

  • Tagging efficiency can vary depending on genomic context

• Implementation protocol:

  • PCR amplification of tagging cassette with homology arms

  • Transformation into S. pombe using lithium acetate method

  • Selection on appropriate media

  • PCR screening of transformants

  • Western blot verification using tag antibodies

This approach has been successfully used to create comprehensive libraries of tagged S. pombe strains, including over 80 transcription factors in recent studies .

How can SPBC106.03 antibodies be used to study protein-protein interactions and complexes?

Several strategies can identify SPBC106.03 interaction partners:

• Immunoprecipitation coupled with mass spectrometry (IP-MS):

  • Standard approach: Anti-SPBC106.03 antibody IP followed by MS

  • Reciprocal approach: IP-MS of suspected interacting proteins to confirm bidirectional interaction

  • Comparative analysis: IP under different conditions (e.g., cell cycle stages, stress responses)

  • Quantitative approach: SILAC or TMT labeling for accurate quantification across conditions

• Proximity labeling methods:

  • BioID approach: Express SPBC106.03-BirA* fusion to biotinylate proximal proteins

  • APEX labeling: SPBC106.03-APEX2 fusion for proximity-dependent biotinylation

  • Analysis of labeled proteins by streptavidin pull-down and MS

• Co-immunoprecipitation with specific antibodies:

  • Targeted validation of key interactions identified by IP-MS

  • Direct co-IP with antibodies against suspected partners

  • Sequential IPs to isolate specific subcomplexes

• Analytical techniques for complex characterization:

  • Size exclusion chromatography to determine complex size

  • Blue native PAGE to preserve native complexes

  • Crosslinking mass spectrometry (XL-MS) to map interaction interfaces

  • Cryo-EM of purified complexes for structural characterization

The IP-MS approach using both low and high salt conditions (150mM and 500mM NaCl) has proven effective for distinguishing stable from transient interactions in S. pombe .

How should SPBC106.03 antibodies be used in developability assessment if this protein has therapeutic potential?

If SPBC106.03 research leads to therapeutic applications, developability assessment would involve:

• Antibody specificity characterization:

  • Comprehensive cross-reactivity testing against human homologs

  • Epitope mapping to identify binding regions

  • Competition assays to evaluate epitope accessibility

• Biophysical property assessment protocols:

  • Hydrophobic interaction chromatography (HIC) to evaluate hydrophobicity

  • Size exclusion chromatography (SEC) to assess aggregation propensity

  • Differential scanning fluorimetry (DSF) for thermal stability

  • Dynamic light scattering (DLS) for colloidal stability

• Analytical characterization:

  • Mass spectrometry for post-translational modification profiling

  • Peptide mapping to confirm sequence coverage

  • Glycosylation analysis if applicable

  • Charge variant analysis by ion-exchange chromatography

• Stability testing:

  • Accelerated stability studies at elevated temperatures

  • Freeze-thaw cycle testing

  • pH stress testing

  • Oxidative stress resistance assessment

The developability workflow described in the literature typically assesses hundreds of antibodies to identify candidates with optimal properties for further development .

How can SPBC106.03 structure and function be analyzed through computational approaches combined with antibody-based validation?

Integrating computational and experimental approaches provides comprehensive characterization:

• Structural prediction and analysis:

  • Homology modeling using related structures as templates

  • AlphaFold or RosettaFold for de novo structure prediction

  • Identification of functional domains and motifs

  • In silico epitope prediction to guide antibody development

  • Structure-based prediction of protein-protein interactions

• Design of validation experiments:

  • Site-directed mutagenesis of predicted functional residues

  • Structure-guided epitope tagging to preserve protein function

  • Antibody epitope mapping to validate structural predictions

  • RosettaAntibodyDesign (RAbD) for computational antibody design

• Integrative analysis pipeline:

  • Predict function based on structural features

  • Design antibodies against specific domains using computational tools

  • Validate predictions experimentally using the antibodies

  • Iterate between computation and experiment to refine models

• Applications of antibody design tools:

  • Optimization of antibody-antigen interfaces

  • Design of antibodies with improved specificity

  • Engineering antibodies for special applications (e.g., intracellular)

  • Structure-based epitope targeting for functional modulation

Computational approaches like RosettaAntibodyDesign provide frameworks for designing antibodies against specific epitopes, which can then be validated experimentally .

What experimental design approaches are most suitable for studying SPBC106.03 function?

A comprehensive experimental design approach would include:

• Hypothesis-driven design elements:

  • Clear statement of research question about SPBC106.03 function

  • Identification of independent and dependent variables

  • Definition of appropriate controls

  • Determination of sample size based on statistical power analysis

• Design strategies to consider:

  • Factorial designs to test multiple factors simultaneously

  • Randomized block designs to control for batch effects

  • Split-plot designs for experiments with multiple manipulation steps

  • Response surface methodology for optimization experiments

• Key experimental variables to control:

  • S. pombe strain background (h+, h-, diploid)

  • Growth conditions (media, temperature, growth phase)

  • Cell synchronization methods if studying cell cycle effects

  • Treatment timing and duration for stress responses

• Statistical considerations:

  • Biological replicates (minimum n=3) for statistical significance

  • Technical replicates to assess measurement variability

  • Appropriate statistical tests based on data distribution

  • Multiple testing correction for high-throughput data

Following established experimental design principles will ensure robust, reproducible results when studying SPBC106.03 function .

What controls are essential when using SPBC106.03 antibodies in different applications?

Essential controls for antibody-based experiments include:

Additional considerations:

• Biological controls:

  • Wild-type versus mutant strains

  • Different growth conditions or cell cycle stages

  • Treatment versus non-treatment samples

• Specificity controls:

  • Pre-immune serum from the same animal

  • Antibody pre-absorbed with immunizing antigen

  • Alternative antibodies targeting different epitopes

• Methodological controls:

  • For S. pombe-specific experiments, other characterized S. pombe proteins as reference points

  • Spike-in controls for quantitative applications

  • Process controls for multi-step protocols

Implementing these controls ensures reliable data interpretation and helps identify potential artifacts or non-specific signals .

How can researchers integrate SPBC106.03 antibody-based studies with genomic and proteomic approaches?

An integrated multi-omics approach provides comprehensive characterization:

• Integration with genomic approaches:

  • ChIP-seq to identify genomic binding sites

  • RNA-seq to correlate binding with gene expression changes

  • CRISPR-Cas9 editing to create functional mutants

  • Genetic interaction mapping (synthetic lethality screens)

• Integration with proteomic approaches:

  • Whole proteome analysis to place SPBC106.03 in context

  • Post-translational modification profiling

  • Protein turnover analysis using pulse-chase methods

  • Proximity labeling to define protein neighborhoods

• Data integration strategies:

  • Correlation analysis between datasets

  • Network analysis to identify functional modules

  • Pathway enrichment to determine biological processes

  • Machine learning approaches for pattern recognition

  • Visualization tools for multi-dimensional data

• Practical implementation:

  • Design experiments with integration in mind (same conditions across platforms)

  • Use consistent strain backgrounds and growth conditions

  • Implement appropriate normalization between datasets

  • Develop computational pipelines for integrated analysis

This integrated approach has been successfully applied in S. pombe studies to create comprehensive atlases of protein function, including transcription factor binding, protein interactions, and regulatory networks .

What quantitative approaches should be used when measuring SPBC106.03 abundance in cells?

Accurate quantification of SPBC106.03 requires:

• Western blot quantification:

  • Use of standard curves with recombinant protein

  • Linear dynamic range determination

  • Digital imaging systems rather than film

  • Proper normalization to loading controls

  • Analysis software for band intensity measurement

• Mass spectrometry-based quantification:

  • Label-free quantification with appropriate standards

  • SRM/MRM for targeted quantification of specific peptides

  • SILAC or TMT labeling for relative quantification

  • Absolute quantification using AQUA peptides

  • Careful selection of proteotypic peptides for SPBC106.03

• Flow cytometry (for tagged versions):

  • Single-cell quantification of fluorescently tagged SPBC106.03

  • Calibration with fluorescent bead standards

  • Compensation for autofluorescence

  • Gating strategies to address cell cycle variations

• Data analysis considerations:

  • Account for S. pombe cell number (approximately 1.43×10^6 actin molecules per cell as reference)

  • Compare to other proteins of known abundance

  • Consider cell-to-cell variability

  • Determine absolute copy number when possible